Table 1.
Baseline characteristics of patients
| Characteristic | Amantadine | Placebo | Total | P-value |
|---|---|---|---|---|
| (N = 16) | (N = 17) | (N = 33) | ||
| Age, mean ± SD, years | 50.69 ± 10.18 | 54.67 ± 9.63 | 52.79 ± 9.94 | 0.154 |
| Female, N (%) | 12 (75) | 8 (47.1) | 21 | |
| > 1 year of college, N (%) | 14 (87.5) | 15 (88.2) | 29 | |
| Recurrent major depression | 10 (62.5) | 10 (58.8) | 20 | |
| Bipolar depression, N (%) | ||||
| Bipolar I | 3 (18.75) | 4 (23.5) | 7 | |
| Bipolar II | 3 (18.75) | 3 (17.6) | 6 | |
| Mean number of depressive episodes per year (past 3 years prior to current episode) | 1.0 ± 1.1 | 1.04 ± 1.2 | 1.02 ± 1.1 | 0.904 |
| Mean duration of depressive episodes (weeks) (past 3 years prior to current episode) | 25.6 ± 21 | 23.7 ± 18 | 24.6 ± 19 | 0.781 |
| Duration of illness (years) | 12.4 ± 9 | 17.6 ± 11 | 15.1 ± 10 | 0.135 |
| Patients with antidepressant or mood stabilizing co-medication, N (%) | 12 (75) | 8 (47.1) | 20 | |
| Amitriptyline | 3 | 3 | 6 | |
| Doxepin | 1 | 1 | 2 | |
| Mirtazapine | 1 | 1 | ||
| Clomipramine | 1 | 1 | ||
| Trimipramine | 1 | 1 | ||
| Tranylcypromine | 1 | 1 | ||
| Moclobemide | 1 | 1 | ||
| Sertraline | 2 | 2 | ||
| Paroxetine | 1 | 1 | 2 | |
| Dibenzepine | 1 | 1 | ||
| Maprotiline | 1 | 1 | ||
| Lithium | 2 | 2 | 4 | |
| Carbamazepine | 2 | 2 | 4 | |
| Valproate | 1 | 1 | ||
| Lorazepam | 3 | 1 | 4 | |
| Alprazolam | 1 | 1 | ||
| Zolpidem | 1 | 1 | ||
| Sulpirid | 1 | 1 | ||
| L-Thyroxin | 2 | 2 | ||
| Dihydroergotamine | 1 | 1 | ||
| Estrogenes | 1 | 1 | 2 | |